Core Insights - Agios Pharmaceuticals focuses on the discovery, development, and commercialization of innovative medicines for rare hematologic diseases, with its lead product being PYRUKYND (mitapivat) for hemolytic anemias [1] - The company reported a significant revenue increase for PYRUKYND, generating $20 million in quarterly revenue, an 86% increase year-over-year, and a full-year revenue of $54 million for 2025 [9] - Agios has approximately $1.2 billion in cash, providing a strong financial position to support its pipeline without immediate financing needs [9] Insider Transactions - Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer, sold 2,959 shares of common stock for about $82,000 on March 5, 2026, marking his first reported sale [5] - The sale was part of a standard procedure following the vesting of 8,100 restricted stock units (RSUs), with Krishnan selling approximately 37% of those shares to cover tax obligations [4][7] - Despite the sale, Krishnan retains 16,200 RSUs that have yet to vest, indicating substantial potential future exposure to the company [3][8] Future Prospects - Agios plans to pursue FDA accelerated approval for mitapivat in sickle cell disease, with a supplemental New Drug Application (sNDA) submission expected in the coming months, which could significantly expand the drug's market [9] - The company is positioned as a niche biotech with a real commercial product and a pipeline targeting rare blood disorders, appealing to investors interested in the rare disease or specialty pharma sectors [10]

Core Insights - Agios Pharmaceuticals has received approval from the Emirates Drug Establishment for PYRUKYND (mitapivat) to treat adult patients with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia in the UAE, making it the only approved medication for this patient group in the region [1][7][4] Company Overview - Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative medicines for patients with rare diseases, particularly in the field of hematology [33] - The company has a distribution agreement with NewBridge Pharmaceuticals to facilitate the regulatory filings and commercialization of PYRUKYND in the Gulf Cooperation Council (GCC) region [3] Industry Context - Thalassemia is a rare inherited blood disorder that significantly impacts hemoglobin production, leading to anemia and various complications [5][6] - The prevalence of thalassemia in the GCC region is approximately 70,000 individuals, highlighting the urgent need for effective treatment options [8] Clinical Trials - The approval of PYRUKYND is based on the results from the ENERGIZE and ENERGIZE-T Phase 3 clinical trials, which demonstrated its efficacy and safety in treating thalassemia [2][9] - The ENERGIZE trial involved 194 patients with non-transfusion-dependent thalassemia, while the ENERGIZE-T trial included 258 patients with transfusion-dependent thalassemia, both trials assessing various endpoints related to hemoglobin response and transfusion reduction [10][11]

Company Overview - Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on therapies for rare hematologic diseases, utilizing expertise in cellular metabolism [6] - The company's strategy involves advancing innovative treatments from research to commercialization, targeting high unmet medical needs [6] - Agios has a pipeline anchored by PYRUKYND and ongoing clinical programs, aiming to establish a competitive position in the rare disease space [6] Financial Performance - As of February 17, 2026, Agios Pharmaceuticals has a market capitalization of $1.63 billion [4] - The company reported a total revenue of $54.03 million for the trailing twelve months (TTM) [4] - Agios posted a net income loss of $412.78 million for the TTM [4] - The stock price was $27.82, reflecting a 17% decline over the past year, underperforming the S&P 500's approximately 13% gain [8] Recent Developments - Commodore Capital sold all 2,338,287 shares of Agios Pharmaceuticals in the fourth quarter, resulting in a decrease of approximately $93.86 million in the position's quarter-end value [1][2] - The company experienced a significant stock price drop of 50% in one day following the Phase 3 RISE UP trial of mitapivat, which failed to reduce sickle cell pain crises [10] - Agios reported a net loss of $108 million in the fourth quarter, compared to a $96.5 million loss in the same quarter the previous year [10] Investment Context - The current investment climate in biotech is shifting towards momentum stocks, with Agios being perceived as underperforming due to execution challenges rather than a lack of assets [11] - The company's capital is concentrated in clinical-stage immunology names, with Agios positioned slightly outside this core theme [11]

Company Overview - Agios Pharmaceuticals is a clinical-stage biopharmaceutical company focused on therapies for rare genetic diseases related to cellular metabolism [6][7] - The company has a marketed product, PYRUKYND (mitapivat), for hemolytic anemias and a pipeline candidate, AG-946, currently in Phase I clinical trials [7] - As of February 13, 2026, Agios shares were priced at $27.96, with a market capitalization of $1.63 billion and a revenue of $54.03 million over the trailing twelve months [4][6] Recent Developments - Rock Springs Capital Management sold 159,379 shares of Agios Pharmaceuticals in Q4 2025, with an estimated transaction value of $5.59 million [1][2] - Following this sale, Rock Springs' position in Agios was valued at $21.75 million, a decrease of $16.72 million from the previous period, reflecting both trading and market price changes [2][10] - The fund's stake in Agios now represents 1.12% of its reported assets under management (AUM), down from 2.2% in the prior quarter [6][10] Market Performance - Agios shares have declined by 16.0% over the past year, underperforming the S&P 500 by 27.8 percentage points [6][10] - The stock price fell significantly after the Phase 3 RISE UP trial of mitapivat met its hemoglobin endpoint but failed to reduce sickle cell pain crises, leading to a 50% drop in November 2025 [9][10] Strategic Focus - Agios targets patients with rare blood disorders, primarily focusing on healthcare providers, specialty clinics, and institutions treating hemolytic anemias [7][8] - The company's strategy emphasizes advancing innovative treatments for underserved patient populations, which supports its competitive position in the biotechnology sector [8]

Q4 and FY 2025 Financial Results and Business Highlights Conference call for investors and analysts 12 February 2026 4 2026 strategic priorities – driving long-term value creation | Execute high-impact launch for AQVESME | | --- | | (mitapivat) in thalassemia | | Potential to expand PK activation franchise into | | sickle cell disease and LR-MDS | | Unlock future value in hematology and other rare | | disease by advancing early-stage pipeline | | Ensure long-term sustainability through disciplined | | capit ...

Business Overview - Agios is positioned for growth and aims for profitability with its existing commercial portfolio[3, 4] - The company has a strong foundation in hematology and aspires to become a sustainable rare disease company[5] - Agios estimates a total global market size of over $10 billion by 2030 for its current pipeline indications[11] Product Pipeline and Approvals - AQVESME (mitapivat) is now approved in the U S for anemia in adults with alpha- or beta-thalassemia, addressing approximately 4,000 addressable patients at launch[7, 17, 23] - AQVESME has a potential to deliver $1 billion in global peak-year-sales across PKD and thalassemia indications[24] - Pyrukynd is approved in the U S , EU, and UK for Pyruvate Kinase Deficiency[7] Clinical Development - In Sickle Cell Disease, 40.6% of patients achieved Hemoglobin response (≥1 g/dL) in the mitapivat trial[37] - Phase 1 tebapivat data demonstrates a 1.2 g/dL increase (2mg) and 1.9 g/dL increase (5mg) in mean change from baseline in Hb across dosing cohorts at Day 28 in SCD patients[44] - In LR-MDS, 40% of low transfusion burden cohort achieved transfusion independence with tebapivat[51]

Core Viewpoint - Agios Pharmaceuticals, Inc. is considered one of the most oversold biotech stocks, with an upgrade from Leerink Partners from Market Perform to Outperform, setting a price target of $34 despite mixed results from its Phase 3 trial for mitapivat in sickle cell disease [1] Group 1: Trial Results - The Phase 3 RISE UP trial achieved its primary endpoint, with 40.6% of patients on mitapivat showing a hemoglobin increase of 1.0 g/dL or more, compared to only 2.9% in the placebo group [2] - However, the treatment did not significantly reduce the annualized rate of sickle cell pain episodes [2] Group 2: Future Catalysts - Leerink Partners identifies the upcoming PDUFA date for thalassemia on December 7 as a potential catalyst that is not currently reflected in stock prices [3] - The firm suggests that this could lead to a commercialization partnership in key markets and broader approval compared to competitor luspatercept [3] Group 3: Company Overview - Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapies for rare diseases, particularly in cellular metabolism [4] - Its leading product, PYRUKYND (mitapivat), targets hemolytic anemias, including sickle cell disease and thalassemia [4]

Core Insights - Agios Pharmaceuticals reported financial results for Q3 2025, highlighting a focus on key milestones for its drug PYRUKYND in treating thalassemia and sickle cell disease [1][2]. Financial Performance - PYRUKYND generated $12.9 million in net revenues for Q3 2025, a 44% increase from $9.0 million in Q3 2024 and a 3% increase from $12.5 million in Q2 2025 [5][6]. - The company reported a net loss of $103.4 million for Q3 2025, compared to a net income of $947.9 million in Q3 2024, which was primarily due to a milestone payment and sale of royalty rights recorded in the previous year [7][17]. Product Development and Regulatory Updates - The PDUFA goal date for PYRUKYND's supplemental New Drug Application (sNDA) for thalassemia has been extended to December 7, 2025, due to a request for a Risk Evaluation and Mitigation Strategy (REMS) [6][11]. - The European Medicines Agency's CHMP has adopted a positive opinion for PYRUKYND in thalassemia, with a final decision expected by early 2026 [5][6]. - The RISE UP Phase 3 trial for sickle cell disease is expected to provide topline results by year-end 2025, potentially leading to a U.S. commercial launch in 2026 [5][11]. Research and Development - The Phase 2b trial for tebapivat in lower-risk myelodysplastic syndromes (MDS) has completed enrollment, with topline results anticipated in early 2026 [5][11]. - Research and Development expenses for Q3 2025 were $86.8 million, an increase of $14.3 million compared to Q3 2024, driven by higher clinical trial costs [11][17]. Cash Position - As of September 30, 2025, Agios had $1.3 billion in cash, cash equivalents, and marketable securities, down from $1.5 billion at the end of 2024 [5][11].

Core Viewpoint - The U.S. FDA has extended the PDUFA goal date for Agios Pharmaceuticals' supplemental New Drug Application (sNDA) for PYRUKYND from September 7, 2025, to December 7, 2025, due to a proposed Risk Evaluation and Mitigation Strategy (REMS) submission to address hepatocellular injury risks [1][2]. Company Overview - Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative medicines for rare diseases, headquartered in Cambridge, Massachusetts [17]. Product Information - PYRUKYND (mitapivat) is an oral pyruvate kinase activator indicated for treating adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia [1][10]. - The sNDA for PYRUKYND is supported by results from the global, randomized, double-blind, placebo-controlled ENERGIZE and ENERGIZE-T Phase 3 trials [3][6]. Clinical Trials - The ENERGIZE trial involved 194 non-transfusion-dependent patients, with a primary endpoint of achieving a hemoglobin response defined as an increase of ≥1.0 g/dL in average hemoglobin concentrations [7]. - The ENERGIZE-T trial included 258 transfusion-dependent patients, focusing on achieving a transfusion reduction response defined as a ≥50% reduction in transfused red blood cell units [8]. Disease Context - Thalassemia is a rare inherited blood disease affecting hemoglobin production, categorized into alpha-thalassemia and beta-thalassemia, leading to anemia and serious complications [4][5]. - Approximately 6,000 adult patients in the U.S. are diagnosed with thalassemia, experiencing significant disease burden and reduced quality of life [5].

Core Viewpoint - Agios Pharmaceuticals has received approval from the Saudi Food and Drug Authority (SFDA) for PYRUKYND (mitapivat) to treat adult patients with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, marking a significant milestone in providing new treatment options for thalassemia patients in Saudi Arabia [1][2]. Company Overview - Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative medicines for rare diseases, headquartered in Cambridge, Massachusetts [13]. - The company has partnered with NewBridge Pharmaceuticals to facilitate the distribution and commercialization of PYRUKYND in the Gulf Cooperation Council (GCC) region, which includes Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Bahrain [3][5]. Product Information - PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency and is now approved for thalassemia in Saudi Arabia [5][6]. - The approval is based on results from the global, randomized, double-blind, placebo-controlled ENERGIZE and ENERGIZE-T Phase 3 trials [2][4]. Market Potential - The SFDA's approval is significant as it is the first of its kind for thalassemia treatment in Saudi Arabia, addressing a community with high prevalence and limited treatment options [2][4]. - Regulatory applications for PYRUKYND are currently under review in the U.S., UAE, and European Union, with a PDUFA goal date of September 7, 2025, for the U.S. [4].